1-(4-异丙基苯基)-3-甲基脲 | 34123-57-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1-(4-异丙基苯基)-3-甲基脲
• 英文名称: 3-(4-isopropylphenyl)-1-methylurea
• 英文别名: monodemethyl isoproturon；monodesmethyl isoproturon；N'-(4-isopropylphenyl)-N-methylurea；Isoproturon-monodemethyl；1-methyl-3-(4-propan-2-ylphenyl)urea
• CAS: 34123-57-4
• 化学式: C₁₁H₁₆N₂O
• mdl: MFCD00227950
• 分子量: 192.261
• InChiKey: DOULWWSSZVEPIN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.363
• 拓扑面积：
  41.1
• 氢给体数：
  2
• 氢受体数：
  1

安全信息

• 海关编码：
  2924299090

反应信息

• 作为反应物：
  描述：

  1-(4-异丙基苯基)-3-甲基脲 在 N-氯代丁二酰亚胺 、 乙酸酐 作用下， 以 乙腈 为溶剂， 生成 6-Amino-1-(2-chloro-4-isopropyl-phenyl)-3-methyl-1H-pyrimidine-2,4-dione
  参考文献：
  名称：

  Design, Synthesis, and Biological Evaluation of 1,2,3,7-Tetrahydro-6H-purin-6-one and 3,7-Dihydro-1H-purine-2,6-dione Derivatives as Corticotropin-Releasing Factor₁ Receptor Antagonists

  摘要：

  A growing body of evidence suggests that CRF1, receptor antagonism offers considerable therapeutic potential in the treatment of diseases resulting from elevated levels of CRF, such as anxiety and depression. A series of novel 1,2,3,7-tetrahydro-6H-purin-6-one and 3,7-dihydro-1H-purine-2,6-dione derivatives was synthesized and evaluated as corticotropin releasing factor-1 (CRF1) receptor antagonists. Compounds within this series, represented by compound 12d (IC50 = 5.4 nM), were found to be highly potent CRF, receptor antagonists. In addition, compounds 12d and 12j were determined to be selective CRF, antagonists. The synthesis, structure-activity relationships and pharmacokinetic properties of compounds within this series is presented.

  DOI：

  10.1021/jm049787k
• 作为产物：
  描述：

  4-异丙基苯异氰酸酯 生成 1-(4-异丙基苯基)-3-甲基脲
  参考文献：
  名称：

  SOPUCH, TOMAS;PSCHEIDT, JIRI;SADLO, LUBOS

  摘要：

  DOI：

文献信息

• Antimitotic Antitumor Agents: Synthesis, Structure−Activity Relationships, and Biological Characterization of <i>N</i>-Aryl-<i>N</i>‘-(2-chloroethyl)ureas as New Selective Alkylating Agents
  作者：Emmanuelle Mounetou、Jean Legault、Jacques Lacroix、René C-Gaudreault

  DOI：10.1021/jm0010264

  日期：2001.3.1

  series of N-aryl-N'-(2-chloroethyl)ureas (CEUs) and derivatives were synthesized and evaluated for antiproliferative activity against a wide panel of tumor cell lines. Systematic structure--activity relationship (SAR) studies indicated that: (i) a branched alkyl chain or a halogen at the 4-position of the phenyl ring or a fluorenyl/indanyl group, (ii) an exocyclic urea function, and (iii) a N'-2-chloroethyl

  合成了一系列的N-芳基-N'-（2-氯乙基）脲（CEU）及其衍生物，并评估了其对多种肿瘤细胞系的抗增殖活性。系统结构-活性关系（SAR）研究表明：（i）苯环或芴基/茚满基4位上的支链烷基链或卤素，（ii）外环脲官能团，和（iii） ）需要N'-2-氯乙基部分以确保明显的细胞毒性。诸如免疫荧光显微镜等生物学实验证实，这些有前途的化合物通过β-微管蛋白的选择性烷基化诱导微管解聚，从而改变了细胞骨架。随后的评估表明，有效的CEU是弱烷基化剂，是非DNA破坏剂，并且不与谷胱甘肽或谷胱甘肽还原酶的硫醇功能相互作用。因此，CEU是新型抗有丝分裂剂的一部分。最后，在评估的一系列CEU中，选择了化合物12、15、16和27用于进一步的体内试验。
• Selective herbicidal compositions
  申请人：Roussel Uclaf

  公开号：US04043796A1

  公开（公告）日：1977-08-23

  Novel selective herbicidal compositions comprising an herbicidally effective amount of at least one compound selected from the group consisting of N-methyl-N-isopropylthio-N'-phenyl-urea, N-methyl-N-(2-chloroethylthio)-N'-(3,4-dichlorophenyl)-urea, N-methyl-N-n-butylthio-N'-(4-isopropylphenyl)-urea, N-methyl-N-isopropylthio-N'-(4-isopropylphenyl)-urea, N-methyl-N-isopropylthio-N'-(3,4-dimethylphenyl)-urea and N-methyl-N-n-butylthio-N'-(3,4-dimethylphenyl)-urea and a carrier and a method of selectively killing weeds in cereal crops and fields of beets.

  新型选择性除草剂组合物包括至少一种化合物，所述化合物选自N-甲基-N-异丙硫基-N'-苯基脲、N-甲基-N-(2-氯乙基硫基)-N'-(3,4-二氯苯基)脲、N-甲基-N-正丁硫基-N'-(4-异丙基苯基)脲、N-甲基-N-异丙硫基-N'-(4-异丙基苯基)脲、N-甲基-N-异丙硫基-N'-(3,4-二甲基苯基)脲和N-甲基-N-正丁硫基-N'-(3,4-二甲基苯基)脲，并且包括载体，以及一种在谷物作物和甜菜田中选择性杀死杂草的方法。
• Rh(III)-Catalyzed Chemoselective C–H Alkenylation and [5 + 1] Annulation with <i>Gem</i>-Difluoromethylene Enabled by the Distinctive Fluorine Effect
  作者：Jian Yang、Wendi Shi、Weijie Chen、Hui Gao、Zhi Zhou、Wei Yi

  DOI：10.1021/acs.joc.1c01012

  日期：2021.7.16

  by the distinctive fluorine effect to provide the different coordination mode of the Rh(III) catalyst binding to the directing group, thereby giving the direct access to difluorinated 2-alkenyl arylureas and 3,4-dihydroquinazolin-2(1H)-ones bearing both an α-quaternary carbon center and a monofluoroalkenyl moiety with broad substrate compatibility and good functional group tolerance. The synthetic application

  多样的有效耦合Ñ -arylureas和宝石-difluoromethylene炔已经通过的Rh（III）已经实现了催化的化学选择性C-H烯基和[5 + 1]环，将其诱导的独特效果的氟，以提供不同的配位模式Rh(III) 催化剂与导向基团结合，从而直接获得带有 α-季碳中心和单氟烯基部分的二氟化 2-烯基芳基脲和 3,4-二氢喹唑啉-2(1 H )-酮具有广泛的底物相容性和良好的官能团耐受性。N在C-H烯基化中的合成应用-吡啶基苯胺、后期 [3 + 2] 环化和所得产物的衍生也被证明可以进一步加强化学发散转化的合成效用。
• Iron(III) photo-induced degradation of isoproturon: correlation between degradation and toxicity
  作者：Fr�d�ric Galichet、Gilles Mailhot、Fr�d�rique Bonnemoy、Jacques Bohatier、Mich�le Bolte

  DOI：10.1002/ps.505

  日期：2002.7

  The degradation of isoproturon photoinduced by Fe(III) was investigated under both artificial and solar light. The monomeric species Fe(OH)2+ present under the experimental conditions ([Fe(III)] = 3 x 10(-4) M) is the main Fe(III) species responsible for the degradation of isoproturon. The process involves the attack on the pollutant by OH radicals generated by irradiation of Fe(OH)2+. The major primary

  研究了在人工和太阳光下，Fe（III）光诱导的异丙隆的降解。在实验条件下（[Fe（III）] = 3 x 10（-4）M）存在的单体Fe（OH）2+是负责异丙隆降解的主要Fe（III）物种。该过程涉及Fe（OH）2+辐射产生的OH自由基对污染物的侵蚀。确定了主要的主要照相产品；它们在降解之前会积聚在溶液介质中。在降解过程中，监测溶液对海洋细菌鱼弧菌（Leijmann＆Neumann）的毒性。它在反应的早期阶段增加，并且在光产物中，N-甲酰基衍生物似乎是引起毒性增加的主要产物。
• Modulators of Immunoinhibitory Receptor PD-1, and Methods of Use Thereof
  申请人：Sharpe Arlene H.

  公开号：US20130022629A1

  公开（公告）日：2013-01-24

  Disclosed are an assay to identify modulators of the PD-1:PD-L pathway and PD-1:PD-L pathway modulators, e.g., compounds and pharmaceutical compositions thereof. Methods for treating diseases influenced by modulation of the PD-1:PD-L pathway such as, for example, autoimmune diseases, inflammatory disorders, allergies, transplant rejection, cancer, immune deficiency, and other immune system-related disorders, are also disclosed.

  本发明揭示了一种鉴定PD-1：PD-L途径调节剂的测定方法和PD-1：PD-L途径调节剂，例如，化合物和制药组合物。本发明还揭示了通过调节PD-1：PD-L途径治疗受PD-1：PD-L途径调节影响的疾病的方法，例如自身免疫疾病、炎症性疾病、过敏、移植排斥、癌症、免疫缺陷和其他与免疫系统相关的疾病。